Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tango Therapeutics ( (TNGX) ) just unveiled an announcement.
On May 12, 2026, Tango Therapeutics announced that directors Alexis Borisy and Kanishka Pothula resigned from the board, effective May 13, 2026, with no disagreements cited over company practices. Sung Lee was appointed Lead Independent Director, chair of the compensation committee, and a member of the nominating and corporate governance committee, reshaping board leadership as the company moves into late-stage clinical development.
On May 13, 2026, Tango reported first-quarter 2026 results, highlighting a cash position of $379.8 million as of March 31, 2026, expected to fund operations into 2028, as it advances vopimetostat toward pivotal development in MTAP-deleted pancreatic cancer. The company reported a $45.5 million net loss on lower R&D spend tied to discontinued programs and higher G&A costs, while outlining 2026 clinical milestones for vopimetostat combinations and TNG456, and recent C-suite hires to support late-stage execution.
The most recent analyst rating on (TNGX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
The score is primarily held back by weak financial performance—large operating losses and heavy free-cash-flow burn alongside declining revenue—offset in part by strong technical momentum (price well above key moving averages with positive MACD). Corporate events are modestly supportive due to leadership and operational build-out, while valuation remains constrained by a loss-making profile and no dividend.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics, Inc. is a Boston-based, clinical-stage biotechnology company focused on discovering novel drug targets and developing next-generation precision cancer medicines. The company leverages the genetic principle of synthetic lethality to design therapies that target critical vulnerabilities in tumors, with a lead emphasis on its PRMT5 program vopimetostat and a broader oncology pipeline.
Average Trading Volume: 3,305,726
Technical Sentiment Signal: Buy
Current Market Cap: $3.39B
Learn more about TNGX stock on TipRanks’ Stock Analysis page.